Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 35.1 kDa 
• Atom Count: 2,483 
• Modelled Residue Count: 288 
• Deposited Residue Count: 302 
• Unique protein chains: 1

 4GIH

Tyk2 (JH1) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE

• PDB DOI:  https://doi.org/10.2210/pdb4GIH/pdb

• Classification: TRANSFERASE/TRANSFERASE INHIBITOR
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): Yes 


• Deposited: 2012-08-08 Released: 2013-06-19 
• Deposition Author(s): Ultsch, M.H.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.217 
• R-Value Work: 0.188 
• R-Value Observed: 0.189 

Literature

Lead identification of novel and selective TYK2 inhibitors.

Liang, J., Tsui, V., Van Abbema, A., Bao, L., Barrett, K., Beresini, M., Berezhkovskiy, L., Blair, W.S., Chang, C., Driscoll, J., Eigenbrot, C., Ghilardi, N., Gibbons, P., Halladay, J., Johnson, A., Kohli, P.B., Lai, Y., Liimatta, M., Mantik, P., Menghrajani, K., Murray, J., Sambrone, A., Xiao, Y., Shia, S., Shin, Y., Smith, J., Sohn, S., Stanley, M., Ultsch, M., Zhang, B., Wu, L.C., Magnuson, S.

(2013) Eur J Med Chem 67: 175-187

• PubMed: 23867602 
• DOI: https://doi.org/10.1016/j.ejmech.2013.03.070
• Primary Citation of Related Structures:  
  4GFM, 4GFO, 4GIH, 4GMY, 4GVJ


• PubMed Abstract: 
  

A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2. Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine 1 as a promising starting point for lead identification. Initial expansion of 3 separate regions of the molecule led to eventual identification of cyclopropyl amide 46, a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile. Analysis of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity.

---

Organizational Affiliation: 

Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Non-receptor tyrosine-protein kinase TYK2	A	302	Homo sapiens	Mutation(s): 6  Gene Names: TYK2 EC: 2.7.10.2
UniProt & NIH Common Fund Data Resources
Find proteins for P29597 (Homo sapiens) Explore P29597  Go to UniProtKB:  P29597
PHAROS:  P29597

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
0X5	B [auth A]	2,6-dichloro-N-{2-[(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide C16 H13 Cl2 N3 O2 IAFNAEGXTKTGHN-UHFFFAOYSA-N

Binding Affinity Annotations
ID	Source	Binding Affinity
0X5	PDBBind:  4GIH	Ki: 4.8 (nM) from 1 assay(s)
	Binding MOAD:  4GIH	Ki: 4.8 (nM) from 1 assay(s)
	BindingDB:  4GIH	Ki: 4.8 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.217 
• R-Value Work: 0.188 
• R-Value Observed: 0.189 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 36.165	α = 90
b = 74.378	β = 90
c = 105.855	γ = 90

Software Package:

Software Name	Purpose
HKL-2000	data collection
PHASER	phasing
BUSTER	refinement
HKL-2000	data reduction
HKL-2000	data scaling

Structure Validation

Entry History 

Deposition Data

• Released Date: 2013-06-19 
Deposition Author(s): Ultsch, M.H.

Revision History  

• Version 1.0: 2013-06-19
  Type: Initial release
  
• Version 1.1: 2013-08-07
  Changes: Database references
• Version 1.2: 2018-01-24
  Changes: Structure summary